Project CASK identified Dr. Mingshan Xue's gene replacement therapy research in 2023 and committed $375,000 in 2024. In 2025, Dr. Xue was named an Oxford-Harrington Rare Disease Scholar — one of the most selective therapeutic development honors in the world. A validation of parent-led science.
